ATHX

Athersys, Inc. (ATHX) | Rumor.io

Athersys

ATHX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ATHX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Oct 18

Athersys, Inc. (ATHX) was suspended from the NASDAQ due to regulatory non-compliance and is now trading OTC.
The company's management has been criticized for not providing timely updates to investors, with some questioning their transparency.
Some analysts believe ATHX could potentially uplist back to the NASDAQ if they address their regulatory issues and provide positive news.

Generated by AI

Sentiment

Of the messages about ATHX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% -5.26
Bearish	—	—	—	5.26% +5.26

Bullish· Oct 17

The company has a $150m license deal, which could potentially trade at $1.5 per share, and has additional revenue streams from stroke and trauma.
There is a possibility of a 50-100% increase in the stock price, with plenty of volume to support it.
The stock has already shown significant growth, bouncing from $0.049 to $0.07 in a short period of time.

Bearish· Apr 2

$ATHX failed its phase 2 trial in ARDS, potentially impacting its potential as a treatment for the condition.
The company's stock price has been affected by insider selling, with a large number of shares being sold by an insider.
Bears have been planning a coordinated bear raid on the stock, which may be contributing to its decline.

Generated by AI

Topics

Of the messages about ATHX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	0%	0%	0%	60%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	100%	100%	100%	40%

Earnings· May 10

Athersys, Inc. ($ATHX) beats earnings per share (EPS) loss estimates by $0.01.
The company slightly beats on revenues.
Athersys beats on EPS by $0.01 and beats on revenue.

Announcements· Oct 10

Athersys, Inc. (ATHX) has entered into a Memorandum of Understanding (MOU) with Healios K.K. for the global rights to develop and commercialize MultiStem for the treatment of acute respiratory distress syndrome (ARDS).
The MOU includes near-term payments of $1.5M to $4.5M and up to $150M in potential development and sales milestones, as well as additional royalties.
Athersys has also reported interim analysis results of the MASTERS-2 clinical study with MultiStem in ischemic stroke, with the Data and Safety Monitoring Board (DSMB) concluding that the current sample size is insufficiently powered to achieve the primary endpoint.

Generated by AI

Community

Of the messages about ATHX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	67.37%
Newcomers	—	—	—	32.63%

Regulars· Oct 17

Athersys Inc. ($ATHX) is facing delisting from NASDAQ, with FINRA announcing the effective date as October 18th, but the company has yet to issue a PR or 8-K notification to shareholders.
Athersys has extended its near-term liquidity with proceeds from a warrant inducement and a global ARDS license with Healios, which may allow the company to explore strategic alternatives.
The stock's float has been traded heavily, with 20.9M shares traded on the day, and a new float rotation of 2.4% gain and 11.7M shares traded has been identified.

Newcomers· Oct 18

The newcomer is concerned about the company's decision to trade on the pink sheets, which they believe is a sign of a troubled stock, and think it could be a $1.5 to $5 stock on buyout terms.
The newcomer is excited about the possibility of Athersys getting backlisted to the Nasdaq, which they believe would be a positive development for the company.
The newcomer is speculating about the potential price of Athersys stock, citing a significant drop and expressing a desire to buy back in if the price dips further.

Generated by AI

Also Discussed

Investors talking about ATHX also mention

#	Name	Attention
1	Vericel CorporationVCEL	0%0
2	Mesoblast Ltd Sponsored ADRMESO	0%0
3	BCLI - Brainstorm Cell Therapeutics Inc.	——
4	ZIOP - ZIOPHARM Oncology, Inc.	——
5	CBLI - Cytocom, Inc.	——
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	Geron CorporationGERN	0%0
8	NVIV - InVivo Therapeutics Holdings Corporation	——
9	Celldex Therapeutics IncCLDX	0%+0
10	Cytokinetics, IncorporatedCYTK	0%-0.01

Athersys, Inc.

Location

Social

What share of all stock conversation is about ATHX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Oct 18

Athersys, Inc. (ATHX) was suspended from the NASDAQ due to regulatory non-compliance and is now trading OTC.
The company's management has been criticized for not providing timely updates to investors, with some questioning their transparency.
Some analysts believe ATHX could potentially uplist back to the NASDAQ if they address their regulatory issues and provide positive news.

Generated by AI

Sentiment

Of the messages about ATHX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% -5.26
Bearish	—	—	—	5.26% +5.26

Bullish· Oct 17

The company has a $150m license deal, which could potentially trade at $1.5 per share, and has additional revenue streams from stroke and trauma.
There is a possibility of a 50-100% increase in the stock price, with plenty of volume to support it.
The stock has already shown significant growth, bouncing from $0.049 to $0.07 in a short period of time.

Bearish· Apr 2

$ATHX failed its phase 2 trial in ARDS, potentially impacting its potential as a treatment for the condition.
The company's stock price has been affected by insider selling, with a large number of shares being sold by an insider.
Bears have been planning a coordinated bear raid on the stock, which may be contributing to its decline.

Generated by AI

Topics

Of the messages about ATHX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	0%	0%	0%	60%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	100%	100%	100%	40%

Earnings· May 10

Athersys, Inc. ($ATHX) beats earnings per share (EPS) loss estimates by $0.01.
The company slightly beats on revenues.
Athersys beats on EPS by $0.01 and beats on revenue.

Announcements· Oct 10

Athersys, Inc. (ATHX) has entered into a Memorandum of Understanding (MOU) with Healios K.K. for the global rights to develop and commercialize MultiStem for the treatment of acute respiratory distress syndrome (ARDS).
The MOU includes near-term payments of $1.5M to $4.5M and up to $150M in potential development and sales milestones, as well as additional royalties.
Athersys has also reported interim analysis results of the MASTERS-2 clinical study with MultiStem in ischemic stroke, with the Data and Safety Monitoring Board (DSMB) concluding that the current sample size is insufficiently powered to achieve the primary endpoint.

Generated by AI

Community

Of the messages about ATHX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	67.37%
Newcomers	—	—	—	32.63%

Regulars· Oct 17

Athersys Inc. ($ATHX) is facing delisting from NASDAQ, with FINRA announcing the effective date as October 18th, but the company has yet to issue a PR or 8-K notification to shareholders.
Athersys has extended its near-term liquidity with proceeds from a warrant inducement and a global ARDS license with Healios, which may allow the company to explore strategic alternatives.
The stock's float has been traded heavily, with 20.9M shares traded on the day, and a new float rotation of 2.4% gain and 11.7M shares traded has been identified.

Newcomers· Oct 18

The newcomer is concerned about the company's decision to trade on the pink sheets, which they believe is a sign of a troubled stock, and think it could be a $1.5 to $5 stock on buyout terms.
The newcomer is excited about the possibility of Athersys getting backlisted to the Nasdaq, which they believe would be a positive development for the company.
The newcomer is speculating about the potential price of Athersys stock, citing a significant drop and expressing a desire to buy back in if the price dips further.

Generated by AI

Athersys

Social

Oct 18

Sentiment

Bullish· Oct 17

Bearish· Apr 2

Topics

Earnings· May 10

Announcements· Oct 10

Community

Regulars· Oct 17

Newcomers· Oct 18

Also Discussed

Athersys, Inc.

Company Information

Location

Also Discussed

Social

Oct 18

Sentiment

Bullish· Oct 17

Bearish· Apr 2

Topics

Earnings· May 10

Announcements· Oct 10

Community

Regulars· Oct 17

Newcomers· Oct 18